PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,185,000 | -47.0% | 500,000 | -26.9% | 1.28% | -44.7% |
Q2 2023 | $9,789,839 | +101.0% | 683,648 | +0.2% | 2.31% | +141.7% |
Q1 2023 | $4,869,673 | -10.3% | 682,027 | +40.9% | 0.96% | -14.6% |
Q4 2022 | $5,431,310 | +55.1% | 484,074 | +53.2% | 1.12% | +45.8% |
Q3 2022 | $3,501,000 | +62.2% | 315,975 | +23.5% | 0.77% | +88.0% |
Q2 2022 | $2,159,000 | – | 255,767 | – | 0.41% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |